Alimera SciencesALIM
Market Cap: $302M
About: Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.
Employees: 158
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
37% more capital invested
Capital invested by funds: $189M [Q1] → $258M (+$69.1M) [Q2]
33% more funds holding
Funds holding: 39 [Q1] → 52 (+13) [Q2]
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
0% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 4 (+0) [Q2]
3.96% less ownership
Funds ownership: 92.47% [Q1] → 88.51% (-3.96%) [Q2]
95% less call options, than puts
Call options by funds: $5K | Put options by funds: $105K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Yi Chen 32% 1-year accuracy 44 / 139 met price target | 8%upside $6 | Neutral Downgraded | 25 Jun 2024 |